(MRX) Marex Ordinary Shares - Overview
Sector: Financial ServicesIndustry: Capital Markets | Exchange NASDAQ (USA) | Currency USD | Market Cap: 2.909m | Total Return 26.6% in 12m
Stock: Liquidity, Clearing, Execution, Derivatives, Platform
Total Rating 56
Risk 27
Buy Signal 0.44
| Risk 5d forecast | |
|---|---|
| Volatility | 55.7% |
| Relative Tail Risk | -10.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.68 |
| Alpha | 14.26 |
| Character TTM | |
|---|---|
| Beta | 0.931 |
| Beta Downside | 1.401 |
| Drawdowns 3y | |
|---|---|
| Max DD | 41.13% |
| CAGR/Max DD | 1.35 |
EPS (Earnings per Share)
Revenue
Description: MRX Marex Ordinary Shares March 03, 2026
Marex Group plc (NASDAQ: MRX) is a UK-based financial services platform that delivers liquidity, market access, and infrastructure across energy, commodities, and financial markets. It operates through four segments-Clearing, Agency & Execution, Market Making, and Hedging & Investment Solutions-offering execution and clearing for metals, agriculture, energy futures, and options, as well as OTC brokering, structured notes, and proprietary technology platforms such as Neon and Agile.
In the most recent fiscal year, Marex generated £1.19 billion in revenue, up 12% year-over-year, with net profit of £152 million, reflecting strong demand for commodity hedging amid heightened energy price volatility. Clearing volumes reached $32 billion, and the firm’s market-making activity in metals and agricultural products grew 8% as global supply-chain disruptions persisted. Key sector drivers include rising commodity price swings, expanding ESG-linked hedging needs, and tighter regulatory requirements for clearing and reporting in Europe and the U.S.
For a deeper dive, you might explore ValueRay’s analysis of MRX.
Headlines to watch out for
- Commodity price volatility drives trading and clearing volumes
- Global energy market shifts impact brokerage and hedging demand
- Interest rate changes affect funding costs and investment returns
- Regulatory compliance costs influence operational expenses
- Competition from larger financial institutions pressures market share
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 453.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 1.37 > 1.0 |
| NWC/Revenue: 336.8% < 20% (prev 51.74%; Δ 285.1% < -1%) |
| CFO/TA 0.05 > 3% & CFO 1.64b > Net Income 453.9m |
| Net Debt (3.79b) to EBITDA (1.46b): 2.60 < 3 |
| Current Ratio: 3.16 > 1.5 & < 3 |
| Outstanding Shares: last quarter (76.1m) vs 12m ago -2.68% < -2% |
| Gross Margin: 64.77% > 18% (prev 0.43%; Δ 6.43k% > 0.5%) |
| Asset Turnover: 16.89% > 50% (prev 16.29%; Δ 0.59% > 0%) |
| Interest Coverage Ratio: 1.56 > 6 (EBITDA TTM 1.46b / Interest Expense TTM 905.6m) |
Altman Z'' 3.62
| A: 0.48 (Total Current Assets 24.53b - Total Current Liabilities 7.75b) / Total Assets 34.68b |
| B: 0.03 (Retained Earnings 982.0m / Total Assets 34.68b) |
| C: 0.05 (EBIT TTM 1.42b / Avg Total Assets 29.49b) |
| D: 0.03 (Book Value of Equity 997.5m / Total Liabilities 33.41b) |
| Altman-Z'' Score: 3.62 = AA |
Beneish M 1.00
| DSRI: 0.92 (Receivables 11.07b/9.55b, Revenue 4.98b/3.96b) |
| GMI: 0.66 (GM 64.77% / 42.92%) |
| AQI: 17.45 (AQ_t 0.29 / AQ_t-1 0.02) |
| SGI: 1.26 (Revenue 4.98b / 3.96b) |
| TATA: -0.03 (NI 453.9m - CFO 1.64b) / TA 34.68b) |
| Beneish M-Score: 6.51 (Cap -4..+1) = D |
What is the price of MRX shares?
As of March 28, 2026, the stock is trading at USD 42.96 with a total of 2,120,435 shares traded.
Over the past week, the price has changed by +21.48%, over one month by -0.72%, over three months by +9.84% and over the past year by +26.58%.
Over the past week, the price has changed by +21.48%, over one month by -0.72%, over three months by +9.84% and over the past year by +26.58%.
Is MRX a buy, sell or hold?
Marex Ordinary Shares has received a consensus analysts rating of 4.25.
Therefore, it is recommended to buy MRX.
- StrongBuy: 3
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 52 | 21% |
| Analysts Target Price | 52 | 21% |
MRX Fundamental Data Overview March 28, 2026
P/E Trailing = 10.5052
P/E Forward = 8.7642
P/S = 1.0137
P/B = 2.0075
Revenue TTM = 4.98b USD
EBIT TTM = 1.42b USD
EBITDA TTM = 1.46b USD
Long Term Debt = 2.33b USD (from longTermDebt, last quarter)
Short Term Debt = 7.75b USD (from shortTermDebt, last quarter)
Debt = 10.17b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.79b USD (from netDebt column, last quarter)
Enterprise Value = -379.8m USD (2.91b + Debt 10.17b - CCE 13.46b)
Interest Coverage Ratio = 1.56 (Ebit TTM 1.42b / Interest Expense TTM 905.6m)
EV/FCF = -0.23x (Enterprise Value -379.8m / FCF TTM 1.62b)
FCF Yield = -427.4% (FCF TTM 1.62b / Enterprise Value -379.8m)
FCF Margin = 32.60% (FCF TTM 1.62b / Revenue TTM 4.98b)
Net Margin = 9.11% (Net Income TTM 453.9m / Revenue TTM 4.98b)
Gross Margin = 64.77% ((Revenue TTM 4.98b - Cost of Revenue TTM 1.75b) / Revenue TTM)
Gross Margin QoQ = 80.45% (prev 39.74%)
Tobins Q-Ratio = -0.01 (set to none) (Enterprise Value -379.8m / Total Assets 34.68b)
Interest Expense / Debt = 7.48% (Interest Expense 760.2m / Debt 10.17b)
Taxrate = 24.94% (76.8m / 308.0m)
NOPAT = 1.06b (EBIT 1.42b * (1 - 24.94%))
Current Ratio = 3.16 (Total Current Assets 24.53b / Total Current Liabilities 7.75b)
Debt / Equity = 8.05 (Debt 10.17b / totalStockholderEquity, last quarter 1.26b)
Debt / EBITDA = 2.60 (Net Debt 3.79b / EBITDA 1.46b)
Debt / FCF = 2.33 (Net Debt 3.79b / FCF TTM 1.62b)
Total Stockholder Equity = 1.15b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.54% (Net Income 453.9m / Total Assets 34.68b)
RoE = 39.46% (Net Income TTM 453.9m / Total Stockholder Equity 1.15b)
RoCE = 40.70% (EBIT 1.42b / Capital Employed (Equity 1.15b + L.T.Debt 2.33b))
RoIC = 11.30% (NOPAT 1.06b / Invested Capital 9.40b)
WACC = 6.42% (E(2.91b)/V(13.08b) * Re(9.26%) + D(10.17b)/V(13.08b) * Rd(7.48%) * (1-Tc(0.25)))
Discount Rate = 9.26% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 3.68%
[DCF] Terminal Value 78.52% ; FCFF base≈1.30b ; Y1≈850.9m ; Y5≈389.1m
[DCF] Fair Price = 99.39 (EV 10.92b - Net Debt 3.79b = Equity 7.13b / Shares 71.7m; r=6.42% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 81.56 | EPS CAGR: 31.48% | SUE: 1.06 | # QB: 1
Revenue Correlation: 48.16 | Revenue CAGR: 71.65% | SUE: 2.84 | # QB: 1
EPS next Quarter (2026-06-30): EPS=1.08 | Chg7d=-0.012 | Chg30d=+0.015 | Revisions Net=+1 | Analysts=5
EPS current Year (2026-12-31): EPS=4.30 | Chg7d=+0.009 | Chg30d=+0.055 | Revisions Net=+2 | Growth EPS=+7.9% | Growth Revenue=+8.6%
EPS next Year (2027-12-31): EPS=4.83 | Chg7d=+0.001 | Chg30d=+0.064 | Revisions Net=-1 | Growth EPS=+12.2% | Growth Revenue=+9.2%
[Analyst] Revisions Ratio: +0.33 (2 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = -0.3% (Discount Rate 9.3% - Earnings Yield 9.5%)
[Growth] Growth Spread = +11.4% (Analyst 11.2% - Implied -0.3%)
P/E Forward = 8.7642
P/S = 1.0137
P/B = 2.0075
Revenue TTM = 4.98b USD
EBIT TTM = 1.42b USD
EBITDA TTM = 1.46b USD
Long Term Debt = 2.33b USD (from longTermDebt, last quarter)
Short Term Debt = 7.75b USD (from shortTermDebt, last quarter)
Debt = 10.17b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.79b USD (from netDebt column, last quarter)
Enterprise Value = -379.8m USD (2.91b + Debt 10.17b - CCE 13.46b)
Interest Coverage Ratio = 1.56 (Ebit TTM 1.42b / Interest Expense TTM 905.6m)
EV/FCF = -0.23x (Enterprise Value -379.8m / FCF TTM 1.62b)
FCF Yield = -427.4% (FCF TTM 1.62b / Enterprise Value -379.8m)
FCF Margin = 32.60% (FCF TTM 1.62b / Revenue TTM 4.98b)
Net Margin = 9.11% (Net Income TTM 453.9m / Revenue TTM 4.98b)
Gross Margin = 64.77% ((Revenue TTM 4.98b - Cost of Revenue TTM 1.75b) / Revenue TTM)
Gross Margin QoQ = 80.45% (prev 39.74%)
Tobins Q-Ratio = -0.01 (set to none) (Enterprise Value -379.8m / Total Assets 34.68b)
Interest Expense / Debt = 7.48% (Interest Expense 760.2m / Debt 10.17b)
Taxrate = 24.94% (76.8m / 308.0m)
NOPAT = 1.06b (EBIT 1.42b * (1 - 24.94%))
Current Ratio = 3.16 (Total Current Assets 24.53b / Total Current Liabilities 7.75b)
Debt / Equity = 8.05 (Debt 10.17b / totalStockholderEquity, last quarter 1.26b)
Debt / EBITDA = 2.60 (Net Debt 3.79b / EBITDA 1.46b)
Debt / FCF = 2.33 (Net Debt 3.79b / FCF TTM 1.62b)
Total Stockholder Equity = 1.15b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.54% (Net Income 453.9m / Total Assets 34.68b)
RoE = 39.46% (Net Income TTM 453.9m / Total Stockholder Equity 1.15b)
RoCE = 40.70% (EBIT 1.42b / Capital Employed (Equity 1.15b + L.T.Debt 2.33b))
RoIC = 11.30% (NOPAT 1.06b / Invested Capital 9.40b)
WACC = 6.42% (E(2.91b)/V(13.08b) * Re(9.26%) + D(10.17b)/V(13.08b) * Rd(7.48%) * (1-Tc(0.25)))
Discount Rate = 9.26% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 3.68%
[DCF] Terminal Value 78.52% ; FCFF base≈1.30b ; Y1≈850.9m ; Y5≈389.1m
[DCF] Fair Price = 99.39 (EV 10.92b - Net Debt 3.79b = Equity 7.13b / Shares 71.7m; r=6.42% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 81.56 | EPS CAGR: 31.48% | SUE: 1.06 | # QB: 1
Revenue Correlation: 48.16 | Revenue CAGR: 71.65% | SUE: 2.84 | # QB: 1
EPS next Quarter (2026-06-30): EPS=1.08 | Chg7d=-0.012 | Chg30d=+0.015 | Revisions Net=+1 | Analysts=5
EPS current Year (2026-12-31): EPS=4.30 | Chg7d=+0.009 | Chg30d=+0.055 | Revisions Net=+2 | Growth EPS=+7.9% | Growth Revenue=+8.6%
EPS next Year (2027-12-31): EPS=4.83 | Chg7d=+0.001 | Chg30d=+0.064 | Revisions Net=-1 | Growth EPS=+12.2% | Growth Revenue=+9.2%
[Analyst] Revisions Ratio: +0.33 (2 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = -0.3% (Discount Rate 9.3% - Earnings Yield 9.5%)
[Growth] Growth Spread = +11.4% (Analyst 11.2% - Implied -0.3%)